Therapy News and Research

RSS

Cordis enrolls first patient in the CYPRESS clinical study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.

31 Aug 2009

Merlin.net Patient Care Network launched in Europe

St. Jude Medical, Inc. today announced European launch of the next generation Merlin.net Patient Care Network (PCN), a secure, Internet-based remote care system for patients with implanted medical devices.

31 Aug 2009

Fifth annual Pathology Visions conference to showcase digital pathology technology and its healthcare applications

The newly formed Digital Pathology Association (DPA), a non-profit organization committed to the advancement of digital pathology applications in healthcare, invites interested pathology professionals to join them for the fifth annual Pathology Visions conference, to be held September 13-15 in San Diego, CA, at the Marriott Hotel and Marina.

31 Aug 2009

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

Celladon Corporation and Momentum Research, Inc. today announced completion of enrollment of the phase 2 double-blind portion of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial. Momentum Research is Celladon’s consulting and management organization with clinical expertise in the development of cardiovascular products and trials.

31 Aug 2009

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into an agreement with Protein Production Services Ltd. (PPS), a leading manufacturing contractor, in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic product.

31 Aug 2009

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Peregrine Pharmaceuticals, Inc., today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program.

31 Aug 2009

DYSlipidemia International Study results presented at the ESC congress

According to a new analysis of 22,000 patients, nearly three-quarters of patients taking statins still had at least one lipid abnormality. These results, from a study conducted by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., which operates in many countries as Merck Sharp & Dohme Limited, were presented today at the European Society of Cardiology (ESC) congress in Barcelona, Spain.

31 Aug 2009

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

POZEN Inc. (NASDAQ:POZN), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for VIMOVO™ (enteric-coated naproxen / immediate release esomeprazole magnesium, formerly know as PN 400).

31 Aug 2009

Research reveals the reason why some patients with Ewing's sarcoma do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy. The research is published online today in the journal Oncogene.

31 Aug 2009

Spinal implant developed by Sanfor Clinic neurosurgeon receives FDA market clearance

Sanford Health, a comprehensive health care provider in the Upper Midwest, announced today a spinal implant developed by Sanford Clinic Neurosurgeon, Wilson Asfora, MD, Sanford Clinic Neurosurgery & Spine, has received United States Food and Drug Administration (FDA) 510(k) market clearance as a lumbar intervertebral body fusion device.

31 Aug 2009

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.

31 Aug 2009

Boston Scientific appoints Senior Vice President for its Cardiac Rhythm Management group

Boston Scientific Corporation (NYSE: BSX) today announced that Ken Stein, M.D., FACC, will join the Company as Senior Vice President and Associate Chief Medical Officer for its Cardiac Rhythm Management (CRM) group. Dr. Stein is currently the Associate Director of Clinical Cardiac Electrophysiology at Weill Cornell Medical Center and Associate Professor of Medicine at Cornell University.

31 Aug 2009

Varian Medical Systems unveils first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities

Varian Medical Systems is introducing the world's first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities for international cancer clinics. Varian's UNIQUE(TM) radiotherapy system is expected to make advanced care more affordable and more widely available to cancer patients around the world.

31 Aug 2009

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.

31 Aug 2009

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

31 Aug 2009

Intermediate dosages of otamixaban reduce acute coronary complications

30 Aug 2009

Clinical data of the REVERSE trial reveals how CRT improves functioning of the heart

Cardiac resynchronization therapy (CRT) is a proven therapy indicated for patients with moderate to severe heart failure. Additional 24-month clinical data presented today on the European cohort of 262 patients in the REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, sponsored by Medtronic, Inc., provides a deeper understanding of how CRT improves the function of the heart, including reduction in heart size and improvements in pumping efficiency, in certain heart failure patients with mild symptoms.

30 Aug 2009

Chiropractor and nutritional educator receives Excellence in Nutritional Education award

Chiropractor and nutritional educator, Dr. Michael Dobbins, has received the Excellence in Nutritional Education award from Standard Process. The Wisconsin-based nutritional whole food supplement manufacturer presented the award during a private reception Thursday evening at Florida Chiropractic Association’s National Convention and Expo event in Orlando, Fla.

29 Aug 2009

Office of Orphan Products Development of the FDA grants Orphan Drug Designation to Quinazoline495

Families of Spinal Muscular Atrophy (Libertyville, IL) announced today that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted Orphan Drug Designation to Quinazoline495 for the treatment of Spinal Muscular Atrophy.

29 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

Therapy News and Research

Cordis enrolls first patient in the CYPRESS clinical study

Merlin.net Patient Care Network launched in Europe

Fifth annual Pathology Visions conference to showcase digital pathology technology and its healthcare applications

Celladon announces completion of patient enrollment for Phase 2 CUPID clinical trial

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

DYSlipidemia International Study results presented at the ESC congress

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

Research reveals the reason why some patients with Ewing's sarcoma do not respond to chemotherapy

Spinal implant developed by Sanfor Clinic neurosurgeon receives FDA market clearance

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Boston Scientific appoints Senior Vice President for its Cardiac Rhythm Management group

Varian Medical Systems unveils first low-energy radiotherapy system with image-guidance and RapidArc treatment capabilities

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Intermediate dosages of otamixaban reduce acute coronary complications

Clinical data of the REVERSE trial reveals how CRT improves functioning of the heart

Chiropractor and nutritional educator receives Excellence in Nutritional Education award

Office of Orphan Products Development of the FDA grants Orphan Drug Designation to Quinazoline495

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News